ResMed Company Profile

Direct answer

ResMed (RMD) is a Health Care company and a constituent of the S&P 500 Equal Weight Index.

This guide covers ResMed's business model, financial metrics, competitive position, risk factors, and index membership as an educational business primer. It does not constitute personalized investment advice or a buy, sell, or price-target recommendation.

What Do the Latest SEC Filings Show for ResMed?

These are figures ResMed reported in its own SEC filings, read from the SEC's XBRL data, so the page has a fixed starting point before any of the research questions below. They describe reported history and are not a forecast.

Item	As reported
Ticker symbol	RMD, RSMDF
SEC industry classification	3841, Surgical & Medical Instruments & Apparatus
Fiscal year ends	June 30
Latest fiscal year reported	FY2025, ended June 30, 2025
Revenue	$5.1 billion
Net income (loss)	$1.4 billion
Operating cash flow	$1.8 billion
Cash and cash equivalents	$1.2 billion

Source: SEC EDGAR: RESMED INC Form 10-K filed August 13, 2026.

Company Snapshot

Field	Value
Company	ResMed
Security line(s)	RMD
SEC CIK	943819
GICS sector	Health Care
GICS sub-industry	Health Care Equipment
Founded / lineage	1989
S&P 500 addition date	2017-07-26
S&P 500 Equal Weight status	Current company constituent as of 2026-09-15
Equal Weight target concept	Equal company weight at quarterly rebalance; nominally 0.20% when there are 500 companies
Canonical Swoopr company URL	`/stocks/companies/resmed/`

What the Company Does

The most defensible high-level description of ResMed starts with its GICS placement in Health Care Equipment. In practical terms, ResMed participates in an industry where a company generally supplies equipment, devices, diagnostics, laboratory tools, consumables, or healthcare technology used in clinical care, research, or life-sciences workflows. That is an analytical starting point, not a substitute for ResMed's own segment disclosure. Use ResMed's latest annual report to find the actual reported segments, economically important products and services, brands, customer groups, and geographies. Where ResMed reports businesses that cross GICS boundaries, keep those distinctions rather than forcing every activity into the Health Care Equipment label. When researching ResMed, the key question is: what operating activity causes a customer to pay the company? Express the answer as a revenue tree rather than a marketing description. Start with the major reported business lines, connect each line to its paying customer, identify the unit that is sold or monetized, then identify whether the economics are recurring, transactional, cyclical, usage-based, regulated, project-based, volume-driven, or spread-driven for ResMed. This turns a company description into a usable model of the business.

How the Company Makes Money

For ResMed, the primary business-model lens is a medical-device, diagnostics, life-science-tools, consumables, or healthcare-technology model. The variables that deserve the first look are procedure volumes, instrument placements, consumable pull-through, installed-base growth, test volumes, new product launches, and research and healthcare budgets. These are industry mechanisms, not ResMed's reported KPIs, so map each one to the metrics ResMed actually discloses. For each material revenue line, check which mechanism drives it, how pricing works, whether customer relationships repeat, and which revenue streams have materially different margin or capital characteristics for ResMed. Revenue quality matters as much as revenue growth. When reviewing ResMed, distinguish growth created by more customers or units from growth created by price, mix, acquisitions, foreign exchange, accounting presentation, or temporary industry conditions. Then ask whether incremental revenue requires proportional new capital, inventory, labor, marketing, or fixed assets for ResMed. The answer determines whether growth can compound with attractive cash economics or whether growth itself consumes substantial capital.

Revenue Engine

The checklist below lists operating variables common in this industry. They are industry-level ideas, not reported figures, so confirm which ones ResMed discloses as KPIs in its latest annual report (Form 10-K), and compare them with ResMed's earnings materials.

Procedure Volumes: test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.

Instrument Placements: test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.

Consumable Pull-Through: test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.

Installed-Base Growth: test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.

Test Volumes: test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.

New Product Launches: test direction, cause, revenue sensitivity, margin effect, and whether the change is durable or cyclical.

Business Segments

Confirm ResMed's exact segment names and reported segment financials in its latest filing. For each reportable segment, look for what it sells, who buys it, how it is priced, its growth and margin characteristics, important geographies, strategic role, and specific risks for ResMed. If management changes segment reporting, compare periods on one consistent definition and note where the restatement begins, rather than splicing unlike periods together for ResMed. Until you have checked the segment table in the filing, avoid treating the consolidated Health Care Equipment classification as if it described every activity. ResMed may contain businesses with very different cyclicality and capital intensity. The highest-value segment analysis often comes from identifying which segment contributes disproportionate profit or cash flow, which segment consumes the most capital, and which segment carries the highest expectations for future growth for ResMed.

Products, Services and Business Lines

This page covers only the economically significant ResMed products, services, platforms, brands and franchises. Each item should be tied to a reportable business line and a monetization mechanism for ResMed. Avoid an exhaustive catalog copied from a corporate website. The useful questions are whether an offering is a gateway product, a recurring revenue source, a high-margin add-on, a regulated necessity, a commodity-like product, or a strategic product that influences customer retention elsewhere in the portfolio for ResMed.

Customers and Buying Behavior

The relevant customer universe for this industry includes hospitals, laboratories, physicians, researchers, universities, biopharma companies, distributors, and patients depending on the product line. For ResMed, the useful questions are which of those customer groups actually matter, whether a small number of customers represent concentration risk, how long purchasing decisions take, who controls the budget, and what makes a customer renew, reorder, switch, or delay purchases. Customer economics often explain why two companies in the same sub-industry can have very different margins and volatility for ResMed. A durable customer relationship can show up through contracts, subscriptions, installed-base dependence, integration costs, distribution access, regulatory qualification, brand preference, or operational reliability for ResMed. Those mechanisms must be evidenced for ResMed; simply saying the company has “loyal customers” is not sufficient. The monitoring framework should watch for weakening retention, lower wallet share, rising incentives, longer sales cycles, or adverse changes in customer concentration for ResMed.

Geographic Exposure

Do not assume ResMed's geographic revenue mirrors where it is headquartered. ResMed's latest annual report (Form 10-K) shows, when disclosed, how revenue, assets, manufacturing, sourcing, regulatory exposure, and major customers are spread across regions. Geography matters because exchange rates, tariffs, export controls, taxes, local competition, political risk, and supply-chain concentration can change the economics even when overall demand for ResMed is stable.

Company Economics

For a Health Care Equipment business, the core cost structure often includes R&D, manufacturing, quality systems, sales/service, regulatory compliance, and inventory. When reviewing ResMed, separate fixed from variable costs and distinguish accounting expenses from cash investment. Then examine operating leverage: if revenue rises by 10%, which costs rise nearly in line, which lag, and which may step up after capacity thresholds for ResMed? The same exercise should be repeated in reverse for a downturn because downside operating leverage is often more important than upside leverage for ResMed. Capital intensity is equally important. ResMed can report attractive operating margins while requiring large amounts of working capital, plant, equipment, acquired intangibles, capitalized software, regulatory capital, or other reinvestment. ResMed's page should therefore reconcile earnings with cash generation and explain which investments are maintenance requirements versus discretionary growth spending.

Financial Statement Guide

Income statement

Start with the revenue lines and expense categories that reflect procedure volumes, instrument placements, and consumable pull-through. Separate organic operating change from acquisitions, divestitures, foreign exchange, accounting reclassifications, and unusual items for ResMed. Margin analysis should show whether changes come from price, mix, volume, productivity, input costs, or overhead absorption for ResMed.

Balance sheet

Identify the assets and liabilities that make the a medical-device, diagnostics, life-science-tools, consumables, or healthcare-technology model work. For ResMed, focus on working capital, debt, goodwill and acquired intangibles, inventory or receivables where material, pension or insurance obligations where applicable, and any industry-specific capital or reserve requirements.

Cash flow statement

Reconcile reported earnings to operating cash flow and then to free cash flow after economically necessary capital expenditures for ResMed. Watch working-capital swings, restructuring cash costs, acquisition spending, stock-based compensation, and other items that can make a single period look unusually strong or weak for ResMed.

Capital expenditure and reinvestment

Determine how much spending merely maintains the existing earnings base and how much expands capacity or capabilities for ResMed. The distinction is especially important when ResMed's growth narrative depends on new facilities, networks, software, R&D, acquisitions, or customer acquisition.

Metrics That Matter Most

These are the measures analysts commonly use to judge a business like ResMed. Look each one up in ResMed's latest annual report (Form 10-K) and quarterly filings (Form 10-Q); companies define some of them differently, so compare like with like.

Metric	What it measures and why it matters	Where to look
Organic Revenue Growth	Revenue growth excluding acquisitions, divestitures and usually foreign currency effects. The adjustments are chosen by each company. Isolates growth of the existing business. Definitions differ, and excluded items can be large, so comparisons across companies need care.	MD&A and earnings release reconciliations. It is typically non-GAAP, so check the company's definition.
Procedure/Test Volume	The number of medical procedures, diagnostic tests or treatments performed or processed in a period. Volume is a core driver of revenue for providers and diagnostics firms. Growth tends to indicate demand, but mix, pricing and reimbursement also shape revenue.	MD&A, earnings releases and segment disclosures. Counting methods are company defined, so check what is included.
Installed Base	The count or value of a company's products currently in use by customers, such as machines, devices or systems in the field. A larger installed base can support recurring service, parts and upgrade revenue. Counting methods vary, and aging units may be retired.	Business section, MD&A and investor materials. It is typically company defined and not audited, so check the definition.
Consumables Mix	The share of revenue from recurring supplies, reagents or disposables used with installed equipment, compared with equipment sales. A higher consumables share usually brings more recurring and predictable revenue. A change can also reflect weaker equipment sales rather than stronger consumables.	Revenue disaggregation in the notes, MD&A and earnings presentations. The categories are company defined, so check how revenue is grouped.
Gross Margin	Revenue minus cost of goods sold, divided by revenue. It shows the share of each sales dollar left after direct production or delivery costs. Investors track it to judge pricing power and cost control. Rising margins often signal strength, but mix shifts or accounting classification can change it without real improvement.	Income statement, with discussion in MD&A. Cost classification differs by company, so compare only after reading the company's own cost of revenue definition.
R&D Intensity	Research and development expense divided by revenue. It shows how much of sales is reinvested in developing new products or technology. Investors use it to gauge commitment to innovation versus near term profit. A change can reflect new programs or cost cuts, and spending alone does not ensure results.	Income statement and R&D footnotes in the annual report. Capitalized development costs may sit elsewhere, so check accounting policy notes.
Backlog	The value of signed orders or contracts not yet recognized as revenue. Definitions vary, for example whether unfunded or cancellable work is included. It gives a view of future revenue visibility. A rising backlog tends to indicate demand, but conversion speed and cancellation risk can weaken it.	MD&A, segment discussion or earnings releases. It is usually a company defined measure, so check how the company counts it.
New-Product Contribution	The share of revenue from products launched within a recent set period, commonly the last few years. Indicates whether innovation is renewing the product line. The cutoff for new is company defined, so figures are hard to compare.	MD&A, earnings calls and investor presentations. It is an operating metric defined by the company, so check the time window.
Free Cash Flow	Cash left after operating needs and capital spending. Commonly defined as operating cash flow minus capital expenditures. Shows cash available for debt repayment, dividends, buybacks or reinvestment. Definitions vary, and one-off working capital swings can distort a single period.	Derived from the cash flow statement. Often shown in earnings releases as a non-GAAP figure, so check the company's own definition.
Regulatory Milestones	Key steps in a product's approval path with health regulators, such as submissions, advisory reviews, approvals, clearances or decision dates. Approvals or delays can change a company's revenue prospects and risk. Outcomes are uncertain, and timelines can shift, so treat dates as targets.	Annual report business section, press releases and regulator databases such as FDA records. Confirm current status against the latest filings.

Competitive Position

Potential sources of competitive durability in this industry include clinical evidence, regulatory approvals, installed base, workflow integration, service networks, and switching costs. For ResMed, any claimed advantage should be tied to evidence: better retention, structurally lower costs, stronger unit economics, sustained share, premium pricing, shorter payback, higher utilization, superior reliability, or another measurable outcome. A “moat” claim without a mechanism and an observable consequence is not persuasive for ResMed. A useful starting peer set inside the current index is Abbott Laboratories, Baxter International, Becton Dickinson, Boston Scientific, Dexcom, Edwards Lifesciences. This is an index peer set, not a claim that every named company is a direct competitor in every product line for ResMed. A full competitor analysis would distinguish direct product competitors, substitute technologies, vertically integrated customers and suppliers, and companies that compete primarily for capital or distribution for ResMed.

Index peer comparison framework

Peer	Why compare it	What to verify
Abbott Laboratories	Current S&P 500 peer classified in Health Care Equipment	Actual product overlap, customer overlap, margins, capital intensity, and geographic mix
Baxter International	Current S&P 500 peer classified in Health Care Equipment	Actual product overlap, customer overlap, margins, capital intensity, and geographic mix
Becton Dickinson	Current S&P 500 peer classified in Health Care Equipment	Actual product overlap, customer overlap, margins, capital intensity, and geographic mix
Boston Scientific	Current S&P 500 peer classified in Health Care Equipment	Actual product overlap, customer overlap, margins, capital intensity, and geographic mix
Dexcom	Current S&P 500 peer classified in Health Care Equipment	Actual product overlap, customer overlap, margins, capital intensity, and geographic mix
Edwards Lifesciences	Current S&P 500 peer classified in Health Care Equipment	Actual product overlap, customer overlap, margins, capital intensity, and geographic mix

Industry Position

ResMed should be analyzed inside the structure of the Health Care Equipment industry rather than in isolation. Map concentration, barriers to entry, buyer power, supplier power, substitution risk, capital requirements, regulation, technology change, and cyclicality for ResMed. Then identify where ResMed sits on the spectrum from price taker to differentiated supplier. This industry map is especially useful when ResMed’s own results look strong: it helps determine whether the improvement reflects company-specific execution or a favorable cycle lifting most participants.

Supply Chain and Dependencies

An initial supply-chain map for this industry connects specialized components, contract manufacturers, regulators, distributors, and hospitals/labs/researchers. The production ResMed page should identify material single-source dependencies, constrained inputs, outsourced manufacturing or service dependencies, logistics bottlenecks, regulated interfaces, and customer concentration. The strongest supply-chain analysis identifies not only who supplies whom but also where bargaining power sits and which participant absorbs volatility when supply or demand changes for ResMed.

Economic Sensitivity

The macro variables most worth testing for this business model are healthcare utilization, hospital capital budgets, research funding, labor constraints, interest rates, and demographics. These are hypotheses, not a claim that every variable has equal influence on ResMed. Link each selected indicator to a specific transmission mechanism - for example, higher rates changing financing costs, weaker employment changing demand or credit, or industrial production changing order volumes for ResMed. Remove macro indicators that do not have a defensible causal path to ResMed's economics.

Company History

Registry data records ResMed's founding or corporate lineage as 1989 and its S&P 500 addition date as 2017-07-26. Those two dates are only anchors. A publishable history should be built from issuer and SEC sources and focus on events that changed the economic identity of ResMed: founding, major product or market entries, mergers, divestitures, restructurings, leadership transitions, regulatory events, crises, and strategic pivots. Avoid trivia that does not explain today’s business.

Verified timeline anchors

1989: Founding or corporate-lineage date recorded in the constituent metadata source. Verify nuanced predecessor history against issuer materials.

2017-07-26: ResMed security line RMD entered the S&P 500 according to the constituent registry used for this snapshot.

2026-09-15: ResMed is treated as a current constituent company of the S&P 500 Equal Weight Index snapshot used by Swoopr.

Capital Allocation

Evaluate ResMed's capital allocation as a hierarchy: first the spending required to maintain the existing business; then high-return organic reinvestment; then strategic acquisitions or divestitures; then balance-sheet decisions; and finally dividends or repurchases. For this industry, ResMed investors should pay particular attention to whether management is reinvesting during peaks in the cycle, paying too much for acquired growth, underfunding maintenance, or returning capital while leverage or other obligations remain elevated. The useful question is not whether ResMed “returns cash to shareholders.” It is whether each dollar has been directed to its highest credible risk-adjusted use. Measure outcomes over multi-year periods using per-share results, returns on invested capital, cash conversion, balance-sheet resilience, and the performance of acquired or newly built assets for ResMed. Repurchases can destroy value if executed at poor prices or merely offset heavy dilution for ResMed.

Growth Drivers

Potential growth for ResMed should be decomposed into observable mechanisms rather than summarized as a single forecast.

Procedure Volumes: verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.

Instrument Placements: verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.

Consumable Pull-Through: verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.

Installed-Base Growth: verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.

Test Volumes: verify management evidence, identify the KPI, separate organic improvement from acquisition/price/mix, and define a disconfirming signal.

Risk Factors

Use ResMed's current risk disclosures to decide which of the following industry risks actually deserve prominence. Each retained risk needs a causal path and a warning signal.

Reimbursement Pressure: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

Procedure Softness: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

Product Recalls: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

Regulatory Delays: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

Hospital Budget Constraints: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

New Technology: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

Supply Shortages: map the exposure to revenue, margin, cash flow, balance sheet, or strategic position; do not copy boilerplate risk language.

Bull, Base and Bear Operating Framework

Bull operating case. A favorable fundamental path for ResMed would combine healthy procedure volumes and instrument placements, stable or improving competitive position, disciplined reinvestment, and cost behavior that allows incremental revenue to convert efficiently into cash. This is not a share-price forecast. The purpose is to state what would have to go unusually well in the ResMed business itself. Base operating case. A normal-execution path would show mixed but manageable movement in procedure volumes, instrument placements, and consumable pull-through, no material erosion in the company’s key competitive mechanisms, and capital allocation consistent with the economics of the business. Results may still be cyclical; “base” does not mean smooth. Bear operating case. A deteriorating path would combine one or more of reimbursement pressure, procedure softness, product recalls, and regulatory delays with weaker operating indicators, pressure on margins or cash conversion, and reduced strategic flexibility. The bear framework should be updated when new filings reveal a different risk concentration for ResMed.

What Could Prove an Investment Thesis Wrong?

Persistent deterioration in organic revenue growth. Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint.

Weakening procedure volumes despite a healthy end market. Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint.

Multi-period margin compression without a credible reinvestment explanation. Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint for ResMed.

Capital allocation that lowers per-share economics or raises balance-sheet risk. Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint for ResMed.

Evidence that customer switching costs, brand, network, cost position, or another claimed advantage is weaker than assumed. Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint for ResMed.

A structural industry change that makes historical comparisons misleading. Define a numeric or filing-based threshold before relying on the thesis so the test is not moved after results disappoint for ResMed.

What Investors Commonly Misunderstand About This Company

GICS classification is not the whole company. ResMed is classified as Health Care Equipment, but actual segments may span adjacent markets. Use segment disclosures.

Revenue growth is not automatically economic improvement. Price, mix, acquisitions, FX, and accounting changes can produce growth with very different cash consequences for ResMed.

The most visible product may not be the profit engine. Verify which ResMed business lines produce operating profit and cash rather than assuming brand visibility equals economic importance.

A strong cycle can masquerade as a stronger moat. Compare performance with peers and end-market conditions before attributing all improvement to execution for ResMed.

Free cash flow needs context. Working-capital timing, deferred investment, restructuring, and stock compensation can make one period unusually strong or weak for ResMed.

What to Monitor

A practical ResMed monitoring list should remain short enough to update every quarter. For each item, store the definition, historical series, source, and why a change would alter the ResMed business thesis.

Organic Revenue Growth: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

Procedure/Test Volume: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

Installed Base: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

Consumables Mix: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

Gross Margin: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review for ResMed.

R&D Intensity: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

Backlog: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review for ResMed.

Procedure Volumes: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

Instrument Placements: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

Consumable Pull-Through: record trend, management explanation, link to revenue/margin/cash flow, and a threshold that would trigger deeper review.

Questions Investors Should Ask

What are ResMed's actual reportable segments, and which segment contributes the most operating profit and cash?

Which of procedure volumes, instrument placements, and consumable pull-through explains most of ResMed's revenue change?

Is ResMed's pricing power strengthening, stable, or weakening, and what evidence proves it?

How much of recent growth is organic versus acquisition, FX, price, mix, or accounting change for ResMed?

What portion of reinvestment is maintenance versus growth?

Which customer group has the strongest bargaining power and why?

Are customer concentration or supplier concentration becoming more material?

Which metric would deteriorate first if the competitive position weakened?

Does operating leverage improve cash economics in growth periods without creating excessive downside in contractions for ResMed?

What is the most important balance-sheet constraint on strategy?

How has management allocated incremental cash over the last full cycle for ResMed?

Have acquisitions improved per-share economics after considering price paid and dilution for ResMed?

Which regulatory change would most directly alter the business model?

What macro variable has the clearest causal link to demand or margins for ResMed?

What evidence would make the current business-model classification obsolete?

S&P 500 Equal Weight Index Context

As of the 2026-09-15 snapshot, ResMed is one of 500 constituent companies represented by 503 security lines in the parent S&P 500 universe used by Swoopr. The S&P 500 Equal Weight Index uses the same constituent companies but resets companies to equal weight at quarterly rebalances for ResMed. With 500 companies, the nominal company target is about 0.20% immediately after a rebalance, before market movement causes weights to drift for ResMed. ResMed therefore has materially different index influence in the equal-weight version than it may have in the capitalization-weighted S&P 500.

Key Takeaways

ResMed is classified in Health Care / Health Care Equipment; use that classification as a starting point, not a replacement for segment research.

The most useful operating variables to verify are procedure volumes, instrument placements, consumable pull-through, and installed-base growth.

The cost structure should be analyzed around R&D, manufacturing, quality systems, and sales/service.

The most relevant monitoring metrics begin with organic revenue growth, procedure/test volume, installed base, consumables mix, and gross margin.

Industry risks include reimbursement pressure, procedure softness, product recalls, and regulatory delays, but only issuer-specific evidence should determine final risk ranking.

Cash generation must be evaluated after maintenance reinvestment, working-capital needs, dilution, and acquisition spending for ResMed.

ResMed receives the same nominal company weight as every other constituent at an S&P 500 Equal Weight quarterly reset, subject to multi-class allocation rules.

Frequently Asked Questions

What does ResMed do?

ResMed is classified by GICS in Health Care Equipment. That means the company participates in an industry where businesses generally supplies equipment, devices, diagnostics, laboratory tools, consumables, or healthcare technology used in clinical care, research, or life-sciences workflows. For ResMed’s exact segments, products, services and customer groups, read Item 1 (Business) of its latest annual report (Form 10-K) on SEC EDGAR.

How does ResMed make money?

The primary analytical lens is a medical-device, diagnostics, life-science-tools, consumables, or healthcare-technology model. Investors should map ResMed's actual disclosed revenue lines to procedure volumes, instrument placements, consumable pull-through, and installed-base growth and distinguish recurring, transactional, cyclical, regulated, or project-based economics as applicable.

What sector is ResMed in?

ResMed is classified in the Health Care sector and Health Care Equipment sub-industry in the constituent snapshot used by Swoopr.

What metrics matter for ResMed?

Metrics commonly watched in this industry include organic revenue growth, procedure/test volume, installed base, consumables mix, gross margin, and R&D intensity. Keep only metrics ResMed reports consistently or that can be reliably calculated from its filings.

What are the main risks for ResMed?

Risks commonly associated with this industry include reimbursement pressure, procedure softness, product recalls, regulatory delays, and hospital budget constraints. The latest 10-K and 10-Q show which of these risks are most material to ResMed now.

Who are ResMed's competitors?

Current index peers in the same or adjacent classification include Abbott Laboratories, Baxter International, Becton Dickinson, Boston Scientific, and Dexcom. This is a research peer set, not a claim of direct competition across every product for ResMed.

What economic conditions affect ResMed?

The strongest macro hypotheses to test are healthcare utilization, hospital capital budgets, research funding, labor constraints, and interest rates. Each should be retained only when there is a clear transmission mechanism to demand, pricing, costs, financing, or capital allocation for ResMed.

Is ResMed in the S&P 500 Equal Weight Index?

Yes. ResMed is treated as a current company constituent in the 2026-09-15 snapshot because the Equal Weight Index uses the same constituent companies as the S&P 500.

What is ResMed's target weight in the Equal Weight Index?

At a quarterly reset, each constituent company is assigned an equal company weight for ResMed. With 500 companies, the nominal target is about 0.20% per company before weights drift with market movements for ResMed.

Does ResMed have multiple share classes in the index?

No multi-class treatment is recorded for this issuer in the current snapshot; Swoopr's registry records security line RMD.

How should an investor use this page?

Use the ResMed dossier as an educational research map: identify the business model, verify the company-specific disclosures in primary sources, track a small set of causal operating metrics, and define thesis-breakers before relying on a conclusion.

Is this investment advice?

No. This dossier is educational research content. It does not provide individualized investment advice, a buy/sell recommendation, or a price target.

References

U.S. Securities and Exchange Commission: ResMed filings

Use the latest 10-K, 10-Q, 8-K, proxy statement, and applicable registration filings for company-specific operating facts.

S&P Dow Jones Indices: S&P 500 Equal Weight Index

Use for index identity and official index documentation.

S&P Dow Jones Indices: U.S. Indices Methodology

Use for equal-weight calculation, rebalancing, and multi-class treatment.

Current constituent metadata snapshot used by Swoopr. Swoopr's constituent registry records ticker, GICS classification, CIK, founding/lineage field, and S&P 500 addition date as of 2026-09-15.

Editorial Verification Gate

Before this ResMed dossier is marked GREEN, an editor or research agent must reconcile every issuer-specific narrative statement against the latest primary sources, populate actual segments and significant products, add current as-of-dated financial and operating metrics where useful, verify management and geography, expand the company timeline with sourced events, and replace any industry hypothesis that does not apply to the issuer. This gate is intentionally explicit: completeness of page structure must never be mistaken for verification of current financial facts.